In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

mAbs

Volumn 5, Issue 6, 2013, Pages 842-850

  Wyant, Timothy ^a   Yang, Lili ^a   Fedyk, Eric ^b  

^a Takeda Cambridge US   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

In vitro; Inflammatory bowel disease; Integrin; Lymphocyte binding; Receptor internalization; Safety profile; Vedolizumab

Indexed keywords

ALPHA4 INTEGRIN; BETA7 INTEGRIN; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; INTEGRIN; INTEGRIN ALPHA4BETA7; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ASSESSMENT; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EXTRAVASATION; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; IN VITRO STUDY; INTERNALIZATION; LYMPHOCYTE ACTIVATION; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TIME TO TREATMENT; ANIMAL; DRUG EFFECTS; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE; METABOLISM; MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FLOW CYTOMETRY; HUMANS; IN VITRO TECHNIQUES; INTEGRINS; LYMPHOCYTES; MICE; PROTEIN BINDING;

EID: 84889872074     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26392     Document Type: Article

References (20)

1. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330:864-75; http://jpet.aspetjournals.org/content/330/ 3/864.long; PMID:19509315; http://dx.doi.org/10.1124/jpet.109.153973.
2. Lazarovits AI, Moscicki RA, Kurnick JT, Camerini D, Bhan AK, Baird LG, Erikson M, Colvin RB. Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 1984; 133:1857-62; http://www.jimmunol.org/content/133/4/1857.long; PMID:6088627.
3. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6:1370-7; http://www.sciencedirect.com/science/ article/pii/S1542356508006174; PMID:18829392; http://dx.doi.org/10.1016/j.cgh. 2008.06.007.
4. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-507; http://www.nejm.org/doi/full/10.1056/NEJMoa042982; PMID:15958805; http://dx.doi.org/10.1056/NEJMoa042982.
5. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18:1470-9; PMID:22147460; http://dx.doi.org/10.1002/ibd.21896.
6. Feagan BG, Rutgeerts P, Sands BE, Sandborn W, Colombel J, Hanauer S, et al. Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial [abstract]. Gastroenterology 2012; 142(Suppl 1):S160-1; http://download.journals. elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508512606076.pdf.
7. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699-710; http://dx.doi.org/10.1056/NEJMoa1215734; PMID:23964932.
8. Hanauer SB, Colombel JF, Feagan BG, Rutgeerts P, Sandborn W, Sands B, et al. Vedolizumab maintenance therapy for Crohn's disease: Results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial [abstract]. Am J Gastroenterol 2012; 107(Suppl 1):S620-1; http://www.nature.com/ ajg/journal/v107/n1s/pdf/ajg2012275a.pdf.
9. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711-21; http://dx.doi.org/10.1056/NEJMoa1215739; PMID:23964933.
10. Chappel MS, Isenman DE, Everett M, Xu YY, Dorrington KJ, Klein MH. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci U S A 1991; 88:9036-40; http://www.pnas.org/content/88/20/ 9036.long; PMID:1833770; http://dx.doi.org/10.1073/pnas.88.20.9036.
11. Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, Scott DM, Lee WC, Cornebise M, Wortham K, et al. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2003; 305:1150-62; http://jpet.aspetjournals.org/content/ 305/3/1150.long; PMID:12626659; http://dx.doi.org/10.1124/jpet.102.047332.
12. Ricard I, Payet MD, Dupuis G. VCAM-1 is internalized by a clathrin-related pathway in human endothelial cells but its alpha 4 beta 1 integrin counter-receptor remains associated with the plasma membrane in human T lymphocytes. Eur J Immunol 1998; 28:1708-18; http://onlinelibrary.wiley.com/ doi/10.1002/(SICI)1521-4141(199805)28:05%3C1708:AID-IMMU1708%3E3.0.CO;2-Y/ abstract;jsessionid=890C87BCE07EBD63A04EC79127C1CEDA.d04t04; PMID:9603478; http://dx.doi.org/10.1002/(SICI)1521-4141(199805)28:05<1708:: AID-IMMU1708>3.0.CO;2-Y.
13. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002; 119:923-9; PMID:12472569; http://dx.doi.org/10.1046/j.1365-2141.2002.03935.x.
14. Raasveld MH, Bemelman FJ, Schellekens PT, van Diepen FN, van Dongen A, van Royen EA, Hack CE, ten Berge IJ. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993; 43:1140-9; PMID:8510394; http://dx.doi.org/10.1038/ki.1993.160.
15. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-28; http://www.nejm.org/doi/full/10.1056/NEJMoa063842; PMID:16908486; http://dx.doi.org/10.1056/NEJMoa063842.
16. Bretscher MS. Endocytosis and recycling of the fibronectin receptor in CHO cells. EMBO J 1989; 8:1341-8; http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC400960/; PMID:2527741.
17. Memmo LM, McKeown-Longo P. The alphavbeta5 integrin functions as an endocytic receptor for vitronectin. J Cell Sci 1998; 111:425-33; http://jcs.biologists.org/content/111/4/425.long; PMID:9443892.
18. Kaiser J, Stockert RJ, Wolkoff AW. Effect of monensin on receptor recycling during continuous endocytosis of asialoorosomucoid. Exp Cell Res 1988; 174:472-80; PMID:3338497; http://dx.doi.org/10.1016/0014-4827(88)90316-3.
19. Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008; 222:9-27; http://onlinelibrary.wiley.com/doi/10. 1111/j.1600-065X.2008.00601.x/pdf; PMID:18363992; http://dx.doi.org/10.1111/j. 1600-065X.2008.00601.x.
20. Wang Y, Liu XP, Zhao ZB, Chen JH, Yu CG. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis 2011; 12:286-94; PMID:21791023; http://dx.doi.org/10.1111/j.1751-2980.2011.00505.x.